CoronaryAtlas logo
CoronaryAtlas
PCSK9
Pathway / Lipid retention & oxidation

PCSK9

PCSK9protein

PCSK9 regulates LDL-receptor degradation, controlling LDL-C levels and subendothelial lipid retention underlying atherosclerosis.

Pathway placement
Cascade stepLipid retention & oxidation
Confidencehigh
RationaleLDL-receptor regulation; elevated PCSK9 increases LDL retention in subendothelium.
Druggability
DruggableYes
Known drugs / candidates10
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000169174

Type I vs non-Type I discrimination

ScoresShared / rises in both
R — rupture / Type-I
67
C — non-Type-I
50
A — assay feasibility
72
E — evidence strength
95
T1DI (composite)
40
Specificity differential (R−C)+16.7
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationmag 2
2anemia / acute blood lossn/a
2hypovolemia / dehydrationn/a
2tachyarrhythmian/a
2hypoxemia / respiratory failuren/a
2hypertensive emergencyn/a
2high-demand / peri-operative stressmag 1
3sudden cardiac deathmag 1
4aPCI-related periproceduraln/a
4bstent thrombosismag 1
4cin-stent restenosismag 2
5CABG-relatedmag 2
Coverage: 6/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 10 supporting references. See the discrimination table for all markers.

Assay & specimen

Validated clinical assay
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich ELISA / immunoassay
Reagent / substrate
Anti-PCSK9 antibody pair
Platform
ELISA/automated
Turnaround · availability
Send-out · Research/clinical

Human genetic evidence

0.670
Open Targets association (myocardial_infarction)
5
GWAS associations
Traits: myocardial infarction

Literature evidence(25)

Clinical trials(20)

Omics datasets(1)